Antacids Market (2026 - 2033)

Antacids Market Summary

The global antacids market size was valued at USD 8.1 billion in 2025 and is projected to grow from USD 8.4 billion in 2026 to USD 11.4 billion by 2033, at a CAGR of 4.4% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 42.7% in 2025. Changing dietary habits are among the major factors expected to fuel the growth of the market during the forecast period.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The increasing prevalence of gastroesophageal reflux disease (GERD), peptic ulcers, and various other digestive disorders, which result in acidity, digestion problems, and heartburn are also expected to drive the market. According to a study published by the National Institutes of Health (NIH) in 2022, 783.95 million people were diagnosed with GERD globally in 2019. The total number of years of life lived with disability (YLD) increased by 77.19%, whereas the total number of prevalent cases increased by 77.53%, and the total number of incident cases increased by 74.79% from 1990 to 2019.

To learn more about this report, Download Free Sample Report

Furthermore, increasing awareness about GERD is anticipated to boost the market growth. According to an article published in the International Foundation for Gastrointestinal, the International Foundation for Functional Gastrointestinal Disorders (IFFGD) encourages patients suffering from GERD-related symptoms, to consult their physicians.

Other factors include rising awareness and availability of over-the-counter (OTC) antacids that offer quick and effective relief from these symptoms and the growing geriatric population that is more prone to digestive issues and requires frequent use of antacids. Changing dietary habits and lifestyle factors such as stress, smoking, alcohol consumption, and obesity that contribute to the development of acid-related disorders can also affect the growth of the market.

In the geriatric population, acid complications create a unique challenge for both general practitioners and gastroenterologists. Moreover, such patients often suffer from various symptomatic disorders such as Barrett's esophagus, and esophageal cancer. For the treatment of such disorders, a combination of treatments is used and the use of antacids in such cases has increased significantly, which is expected to drive the market growth over the forecast period.

Market Dynamics

The antacid market is characterized by sustained demand for over the counter gastrointestinal therapies used for the management of heartburn, acid indigestion, and mild gastroesophageal reflux symptoms. Market activity remains concentrated around calcium carbonate based antacids and alginate containing formulations, particularly in North America and Europe where self medication rates are high. Manufacturers are focusing on line extensions through sugar free variants, flavored formulations, and portable dosage formats to maintain brand competitiveness in a mature product category. The market is also experiencing increasing competition from proton pump inhibitors and H2 receptor antagonists, which are widely used for longer duration acid suppression. Retail pharmacies continue to account for a significant share of product distribution, while online pharmacy channels are gaining importance across developed markets. In emerging economies, expanding consumer access to self care medications and broader pharmacy penetration are supporting product consumption. Generic competition remains a key factor affecting pricing across multiple regional markets.

Analyst Perspective

The antacid market continues to be a mature segment of the gastrointestinal therapeutics industry, with demand supported by the consistent use of over the counter products for heartburn, acid indigestion, and reflux symptom management. Market competition is centered on established brands, generic alternatives, formulation differentiation, and distribution reach. Tablet formulations continue to account for a significant share of consumption due to convenience and broad availability, while liquid products maintain demand among specific patient groups. The market is witnessing increased emphasis on consumer friendly formats, including flavored, sugar free, and portable formulations. In addition, online pharmacy expansion and growing consumer engagement in self care are creating opportunities for broader product accessibility. Strategic investments in digestive health portfolios and brand expansion activities are expected to remain key competitive factors across major markets.

Type Insights

Based on type, the tablet segment led the market with the largest revenue share of 50.2% in 2025. The presence of chewable tablets in different flavors helps in improving patient adherence to the medication. In addition, tablets can provide the exact amount of dosage to the patients compared to other dosage forms and also they are easy to store compared to other counterparts. These factors can be attributed to the segment growth over the forecast period. Some well-known brands of chewable tablets include TUMS, manufactured by the Haleon Group of Companies; Alka-Seltzer, manufactured by Bayer AG; and Rolaids, manufactured by Sanofi Consumer Healthcare.

Strict regulations regarding formulations, labeling, and other elements associated with medicines have been stimulating reformulations, product relaunches, and enhanced R&D efforts in this market. For instance, in November 2025, the U.S. Food and Drug Administration announced approval for reformulated ranitidine tablets, which marked return of widely used acid-reducing medicine the U.S. industry. Such developments highlight the growth trends in this market.

The liquid segment is expected to grow at a significant CAGR over the forecast period. The presence of key players, such as Pfizer Inc., GlaxoSmithKline plc. and Dabur offering liquid antacids is estimated to boost the segment growth. Also, the liquid dosage form is one of the most favored choices for children and the elderly population due to its palatable taste. This factor is also anticipated to foster market growth.

End Use Insights

Based on end use, the retail pharmacy segment led the market with the largest revenue share of 72.2% in 2025. Easy accessibility, increasing number of retail pharmacies operated by organized retail businesses, and assistance provided by local pharmacist in making right choices for OTC medicines, are some of the key growth drivers for this segment. Retail pharmacies have been offering variety of products with similar symptom relief properties, which enables additional choices for the patients, leading to greater engagements.

To learn more about this report, Download Free Sample Report

Presence of large retail businesses in this segment is anticipated to fuel growth in forecast period. Multiple large-scale operators in retail industry have been adopting automation and enhanced warehousing techniques to develop competitive advantage over others. For instance, in May 2025, Walmart announced opening of its centralized prescription processing facility, spanning across 102,000-square-foot, in Frederick, Maryland. The facility is developed to address 100,000 prescriptions each day, to facilitate seamless operational support for nearly 700 stores across multiple states. It also announced ongoing facility developments in Phoenix, Arizona and Republic, Missouri. Such advancements are likely to support growth of retail pharmacy segments in this market.

Online pharmacy is anticipated to grow at the fastest CAGR over the forecast period, owing to perks such as quick home delivery, diversity in options for goods, better pricing, and discounts. Some of the top online pharmacy companies in the U.S. include Sesame, Amazon Pharmacy, CVS, Pill Pack, Blink Health, and GeniusRx. In February 2026, Amazon announced its plans to expand same-day prescription delivery through Amazon Pharmacy to 4,500 U.S. locations by the end of 2026. Such developments are expected to support segment growth during the forecast period.

Regional Insights

North America Antacids Market Trends

North America dominated the antacids market with the largest revenue share of 42.7% in 2025. The antacids  market in the U.S. held the largest share in the North America region in 2025. This is attributed to a well-established healthcare system and infrastructure, easy information availability, and a strong retail pharmacy presence in the region. In addition, the presence of multiple companies engaged in the manufacturing and marketing of antacids in the regions also contributes to the growth experienced by this regional industry.

To learn more about this report, Download Free Sample Report

Asia Pacific Antacids Market Trends

Asia Pacific antacids industry is projected to register the fastest CAGR over the forecast period, which is attributed to high unmet clinical needs, increasing awareness about the immediate relief benefits offered by the antacids, and the growing network of retail pharmacies in countries such as India and China. The presence of various manufacturing organizations such as Haleon, Reckitt Benckiser, Sanofi, Bayer AG, Johnson & Johnson, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and others also adds significant strength to the region’s growth potential.

Key Antacids Company Insights

The competitive environment of the market is highly fragmented, with the presence of several multinational players and small-scale companies, competing to gain higher market share. New product launches, geographical expansion, and joint ventures are some of the key strategies undertaken by key players in the market.

Key Antacids Companies

The following key companies have been profiled for this study on the antacids market.

• GSK plc.

• Bayer AG

• Boehringer Ingelheim International GmbH

• Dr. Reddy’s Laboratories Ltd.

• Sanofi

• Reckitt

• Sun Pharmaceutical Industries Ltd.

• Takeda Pharmaceutical Company Limited

• Pfizer Inc.

• Procter & Gamble

Recent Developments

• In January 2026, Wonderbelly, one of the digestive health company, engaged in clean-label product developments, was acquired by Procter & Gamble. Becoming part of P&G’s personal health care portfolio, Wonderbelly is expected to strengthen P&G position in consumer health industry.

• In July 2024, Phathom Pharmaceuticals, a biopharmaceutical company dedicated to the development and market launch of next-generation therapies for gastric acid disorders, announced the approval of the FDA for VOQUEZNA (vonoprazan) 10 mg tablets, which are used to reduce the heartburn related to Gastroesophageal Reflux Disease (GERD) in adults.

Global Antacids Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antacids market report based on type, end use, and region:

To learn more about this report, Download Free Sample Report

• Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Tablet

  • Liquid

  • Others

• End-use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The antacids market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each antacids segment quantified using the revenue-capture definitions in the table below.

Estimation Model

To learn more about this report, Download Free Sample Report

The Antacid Market was estimated using a commodity flow and revenue based market analysis approach. The methodology began with the identification of key manufacturers and commercially available antacid products across major markets. Leading brands and generic products were benchmarked based on product portfolios, sales performance, pricing, dosage forms, distribution reach, and geographic presence. Revenue generated from antacid products was assessed through company annual reports, investor presentations, regulatory filings, product catalogs, industry publications, and trade databases. Product level revenues were aggregated to estimate market revenues across tablet, liquid, and other dosage form segments.

The market estimates were further validated through an assessment of consumption patterns, retail sales trends, pharmacy channel distribution, and product utilization across key regions. Market shares of leading manufacturers were evaluated based on brand presence, distribution networks, and product availability. Data triangulation was performed by comparing company revenues, product sales, and channel level demand trends to ensure consistency across market estimates. Forecast projections incorporated changes in consumer purchasing behavior, generic competition, e commerce penetration, product innovation, and expansion of digestive health product portfolios.

Delivered Customizations

This report has been delivered with the following In-depth customizations